Ovid Therapeutics appointed Charles Carter as Chief Financial Officer, principal financial officer, principal accounting officer and secretary effective July 6, 2026, as Jeffrey Rona transitioned from those roles.
| IndividualJeffrey RonaCharles Carter | RoleFormer Chief Business and Financial Officer; principal financial officer; principal accounting officer; secretaryChief Financial Officer; principal financial officer; principal accounting officer; secretary | Type of ChangeTransition/SeparationAppointment | Effective DateJuly 6, 2026July 6, 2026 | ReasonMutual agreement to transition; not due to disagreement over accounting or financial mattersBoard appointment following Rona's transition | Replacement InfoSucceeded by Charles CarterReplaced Jeffrey Rona | Background DetailsNot disclosedAge 59; SVP Finance & Financial Planning at Ovid (Oct 2024–Jul 2026); prior CFO roles at CERo, iCAD, GI Dynamics; MBA and MS from The University of Chicago; BS from Colgate University | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.